Recce Pharmaceuticals (ASX:RCE) Secures China Patent for Anti-Infectives
Recce Pharmaceuticals (ASX:RCE) secures a China Patent for its RECCE® anti-infectives, enhancing its global intellectual property portfolio.
Tag: Regulatory News & Compliance
Victory Metals Limited (ASX:VTM) Responds to ASX Query
Victory Metals Limited (ASX:VTM) addresses ASX’s query on significant trading activity and confirms compliance with listing rules.
Dimerix (ASX:DXB) Successfully Completes IDMC Review for ACTION3 Phase 3 Trial
Dimerix (ASX:DXB) successfully completes IDMC review of ACTION3 Phase 3 trial, affirming DMX-200’s safety profile.
Dexus (ASX:DXS) Secures Injunction in APAC Governance Dispute
Dexus (ASX:DXS) secures an injunction against APAC, safeguarding shareholder rights until an August court ruling.
James Hardie Industries plc (ASX:JHX) Releases Annual Asbestos Liability Valuation
James Hardie Industries plc (ASX:JHX) unveils its annual valuation of asbestos-related liabilities, showing an increase to $1,472.4 million and outlining significant financial and regulatory updates.
Mount Burgess Mining N.L. (ASX:MTB) Resumes Trading Following Court Orders
Mount Burgess Mining (ASX:MTB) resumes trading on ASX after Supreme Court of Western Australia grants favorable court orders.
NSX Limited (ASX:NSX) Announces Scheme of Arrangement with CNSX Markets Inc.
NSX Limited (ASX:NSX) announces its acquisition by CNSX Markets Inc. with a 59% premium offer, enhancing Australia’s capital markets competitiveness.
Arizona Lithium (ASX:AZL) Receives Approval for Phase 1 Production at Prairie Project
Arizona Lithium (ASX:AZL) secures Phase 1 production approval for Prairie Project, enhancing resource estimates and marking a first in Saskatchewan.
Diablo Resources (ASX:DBO) Identifies New Copper Targets in Phoenix Project
Diablo Resources (ASX:DBO) identifies four high-priority copper targets in Utah’s Phoenix Project, planning drilling in Q3 2025.
Mesoblast (ASX:MSB) Receives 7-Year FDA Orphan Drug Approval for Ryoncil™
Mesoblast (ASX:MSB) secures 7-year FDA orphan-drug exclusivity for Ryoncil™ in treating pediatric SR-aGvHD, strengthening its IP protection.